A prior multi‐center ELN study which included 48 patients with CVT and MPN recruited from 11 hematology centers, predated discovery of the CALR mutation; moreover, neurological sequelae were not assessed in that particular study.2 The gene discussed is CALR; the disease is myeloproliferative neoplasm.